comparemela.com

Latest Breaking News On - Ayman grada - Page 1 : comparemela.com

Why are dermatologists prescribing women a blood pressure drug for acne?

Antibiotics for Acne: Groundbreaking Study Shows Why One Works Best

Almirall launches Klisyri

Almirall is introducing Klisyri (tirbanibulin), for the topical treatment of actinic keratosis of the face and scalp. Klisyri is a novel, topical, first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile. AK is the second most common diagnosis made by dermatologists in the United States. It is estimated that more than 40 million Americans develop AKs each year. Ayman Grada, head of R&D and medical affairs at Almirall U.S. said that the incidence of actinic keratosis has been increasing, including in younger adults. Patients may prefer a treatment option with a short duration and proven safety and tolerability profile. The data for Klisyri offers this, as well as demonstrating efficacy for both face and scalp actinic keratoses.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.